Cen Ling-Ping, Liang Jia-Jian, Chen Jian-Huan, Harvey Alan R, Ng Tsz Kin, Zhang Mingzhi, Pang Chi Pui, Cui Qi, Fan You-Ming
Joint Shantou International Eye Center, Shantou University and The Chinese University of Hong Kong, Shantou, PR China.
Joint Shantou International Eye Center, Shantou University and The Chinese University of Hong Kong, Shantou, PR China.
Neuroscience. 2017 Feb 20;343:472-482. doi: 10.1016/j.neuroscience.2016.12.027. Epub 2016 Dec 23.
The aim of the present study was to determine whether adeno-associated viral vector (AAV) mediated transfer of ciliary neurotrophic factor (CNTF) and RhoA shRNA has additive effects on promoting the survival and axon regeneration of retinal ganglion cells (RGCs) after optic nerve crush (ONC). Silencing effects of AAV-RhoA shRNA were confirmed by examining neurite outgrowth in PC12 cells, and by quantifying RhoA expression levels with western blotting. Young adult Fischer rats received an intravitreal injection of (i) saline, (ii) AAV green fluorescent protein (GFP), (iii) AAV-CNTF, (iv) AAV-RhoA shRNA, or (v) a combination of both AAV-CNTF and AAV-RhoA shRNA. Two weeks later, the ON was completely crushed. Three weeks after ONC, RGC survival was estimated by counting βIII-tubulin-positive neurons in retinal whole mounts. Axon regeneration was evaluated by counting GAP-43-positive axons in the crushed ON. It was found that AAV-RhoA shRNA decreased RhoA expression levels and promoted neurite outgrowth in vitro. In the ONC model, AAV-RhoA shRNA by itself had only weak beneficial effects on RGC axon regeneration. However, when combined with AAV-CNTF, AAV-RhoA shRNA significantly improved the therapeutic effect of AAV-CNTF on axon regeneration by nearly two fold, even though there was no significant change in RGC viability. In sum, this combination of vectors increases the regenerative response and can lead to more successful therapeutic outcomes following neurotrauma.
本研究的目的是确定腺相关病毒载体(AAV)介导的睫状神经营养因子(CNTF)和RhoA短发夹RNA(shRNA)的转导对视神经挤压(ONC)后视网膜神经节细胞(RGCs)的存活和轴突再生是否具有相加作用。通过检测PC12细胞中的神经突生长以及用蛋白质印迹法量化RhoA表达水平,证实了AAV-RhoA shRNA的沉默效果。成年Fischer大鼠接受玻璃体内注射:(i)生理盐水,(ii)AAV绿色荧光蛋白(GFP),(iii)AAV-CNTF,(iv)AAV-RhoA shRNA,或(v)AAV-CNTF和AAV-RhoA shRNA的组合。两周后,完全挤压视神经。ONC三周后,通过计数视网膜全层中βIII-微管蛋白阳性神经元来估计RGC存活情况。通过计数挤压的视神经中GAP-43阳性轴突来评估轴突再生。结果发现,AAV-RhoA shRNA在体外降低了RhoA表达水平并促进了神经突生长。在ONC模型中,单独的AAV-RhoA shRNA对RGC轴突再生只有微弱的有益作用。然而,当与AAV-CNTF联合使用时,AAV-RhoA shRNA显著提高了AAV-CNTF对轴突再生的治疗效果,提高了近两倍,尽管RGC活力没有显著变化。总之,这种载体组合增加了再生反应,并能在神经创伤后带来更成功的治疗结果。